Cargando…
Improvement of urinary symptoms after bladder biopsy: A case of pathologically proven allergy‐related cystitis during administration of nivolumab
INTRODUCTION: We present a case of cystitis, which was considered to be an immune‐related adverse event associated with nivolumab administration. CASE PRESENTATION: A 47‐year‐old man suffered from sudden onset urinary symptoms after 18 cycles of nivolumab treatment for stage IV pulmonary adenocarcin...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294138/ https://www.ncbi.nlm.nih.gov/pubmed/34308272 http://dx.doi.org/10.1002/iju5.12286 |
_version_ | 1783725178020167680 |
---|---|
author | Yajima, Shugo Nakanishi, Yasukazu Matsumoto, Shunya Tanabe, Kenji Sugano, Masato Masuda, Hitoshi |
author_facet | Yajima, Shugo Nakanishi, Yasukazu Matsumoto, Shunya Tanabe, Kenji Sugano, Masato Masuda, Hitoshi |
author_sort | Yajima, Shugo |
collection | PubMed |
description | INTRODUCTION: We present a case of cystitis, which was considered to be an immune‐related adverse event associated with nivolumab administration. CASE PRESENTATION: A 47‐year‐old man suffered from sudden onset urinary symptoms after 18 cycles of nivolumab treatment for stage IV pulmonary adenocarcinoma. Urine culture and urine cytology were both negative. The symptoms were inferred to be related to nivolumab administration, and a bladder biopsy under spinal anesthesia was performed. The histopathological examination showed the evidence of allergic‐related cystitis. We planned to administer corticosteroids, but the urinary symptoms disappeared after the bladder biopsy. Nivolumab treatment was continued without recurrent bladder symptoms. CONCLUSION: We reported a case of cystitis after treatment with nivolumab, which served as a reminder to consider the possibility of immune‐related adverse events as a potential cause for any symptoms that develop during treatment with immuno‐oncology drugs. |
format | Online Article Text |
id | pubmed-8294138 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82941382021-07-23 Improvement of urinary symptoms after bladder biopsy: A case of pathologically proven allergy‐related cystitis during administration of nivolumab Yajima, Shugo Nakanishi, Yasukazu Matsumoto, Shunya Tanabe, Kenji Sugano, Masato Masuda, Hitoshi IJU Case Rep Case Reports INTRODUCTION: We present a case of cystitis, which was considered to be an immune‐related adverse event associated with nivolumab administration. CASE PRESENTATION: A 47‐year‐old man suffered from sudden onset urinary symptoms after 18 cycles of nivolumab treatment for stage IV pulmonary adenocarcinoma. Urine culture and urine cytology were both negative. The symptoms were inferred to be related to nivolumab administration, and a bladder biopsy under spinal anesthesia was performed. The histopathological examination showed the evidence of allergic‐related cystitis. We planned to administer corticosteroids, but the urinary symptoms disappeared after the bladder biopsy. Nivolumab treatment was continued without recurrent bladder symptoms. CONCLUSION: We reported a case of cystitis after treatment with nivolumab, which served as a reminder to consider the possibility of immune‐related adverse events as a potential cause for any symptoms that develop during treatment with immuno‐oncology drugs. John Wiley and Sons Inc. 2021-03-23 /pmc/articles/PMC8294138/ /pubmed/34308272 http://dx.doi.org/10.1002/iju5.12286 Text en © 2021 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Case Reports Yajima, Shugo Nakanishi, Yasukazu Matsumoto, Shunya Tanabe, Kenji Sugano, Masato Masuda, Hitoshi Improvement of urinary symptoms after bladder biopsy: A case of pathologically proven allergy‐related cystitis during administration of nivolumab |
title | Improvement of urinary symptoms after bladder biopsy: A case of pathologically proven allergy‐related cystitis during administration of nivolumab |
title_full | Improvement of urinary symptoms after bladder biopsy: A case of pathologically proven allergy‐related cystitis during administration of nivolumab |
title_fullStr | Improvement of urinary symptoms after bladder biopsy: A case of pathologically proven allergy‐related cystitis during administration of nivolumab |
title_full_unstemmed | Improvement of urinary symptoms after bladder biopsy: A case of pathologically proven allergy‐related cystitis during administration of nivolumab |
title_short | Improvement of urinary symptoms after bladder biopsy: A case of pathologically proven allergy‐related cystitis during administration of nivolumab |
title_sort | improvement of urinary symptoms after bladder biopsy: a case of pathologically proven allergy‐related cystitis during administration of nivolumab |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294138/ https://www.ncbi.nlm.nih.gov/pubmed/34308272 http://dx.doi.org/10.1002/iju5.12286 |
work_keys_str_mv | AT yajimashugo improvementofurinarysymptomsafterbladderbiopsyacaseofpathologicallyprovenallergyrelatedcystitisduringadministrationofnivolumab AT nakanishiyasukazu improvementofurinarysymptomsafterbladderbiopsyacaseofpathologicallyprovenallergyrelatedcystitisduringadministrationofnivolumab AT matsumotoshunya improvementofurinarysymptomsafterbladderbiopsyacaseofpathologicallyprovenallergyrelatedcystitisduringadministrationofnivolumab AT tanabekenji improvementofurinarysymptomsafterbladderbiopsyacaseofpathologicallyprovenallergyrelatedcystitisduringadministrationofnivolumab AT suganomasato improvementofurinarysymptomsafterbladderbiopsyacaseofpathologicallyprovenallergyrelatedcystitisduringadministrationofnivolumab AT masudahitoshi improvementofurinarysymptomsafterbladderbiopsyacaseofpathologicallyprovenallergyrelatedcystitisduringadministrationofnivolumab |